MSF co-signed an open letter to Cepheid calling for improved access to GeneXpert TB diagnostic tests

MSF and others call on Gavi to immediately start its hepatitis B birth dose vaccination programme

CSO letter to ViiV on access to HIV PrEP drug cabotegravir

UK civil society letter to UK government on TRIPS Waiver

Letter from 40+ CSOs calling on EU to refrain from rushing WTO members to adopt a purported proposal on IP rights and COVID-19.

US CSO letter to President Biden on COVID-19 TRIPS Waiver leaked text

CSO letter to WTO Director General on COVID-19 TRIPS Waiver

After WTO Ministerial postponement, CSOs sent an open letter to the Chair of the WTO TRIPS Council to stop delaying negotiations on the TRIPS Waiver

In The Lancet, MSF Access Campaign challenges the status quo of patents and other intellectual property blocking access to COVID-19 medical tools.

MSF joined other CSOs in this open letter to the WTO Director General on the TRIPS Waiver, calling for equitable access to COVID-19 medical tools

Letter from MSF and civil society organisations to diagnostics corporation Cepheid calling for reinstating launch of TB testing system GeneXpert Omni.

MSF and civil society organizations (CSOs) in South Africa sent the following letter to the embassies of countries blocking or delaying the TRIPS Waiver on COVID-19 medical tools.

TB LAM tests for TB diagnosis must be adopted by countries with high TB burden, and Abbott must make its current TB LAM test more accessible

MSF sent another open letter urging AbbVie to make glecaprevir/pibrentasvir (G/P) accessible for people with hepatitis C in LMICs

Open letter from CSOs to the European Commission to stop blocking the WTO TRIPS Waiver on intellectual property of COVID-19 medical tools

Open letters to US President Biden and to US Trade Representative to swiftly implement the WTO TRIPS Waiver on IP of all COVID-19 medical tools

Open letter sent to Gilead and Viatris calling for affordable access to liposomal amphotericin B (L-AmB) to treat mucormycosis (black fungus)

Open letter sent to WHO and ACT-A calling for access to liposomal amphotericin B (L-AmB) to treat mucormycosis (black fungus) and other diseases